Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations

NCT01819428 is registered in ClinicalTrials.gov with National OncoVenture as lead sponsor.

NCT NCT01819428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01819428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations
Lead sponsor
National OncoVenture
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2013
Completion date
November 30, 2015
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung stage iiib, adenocarcinoma of lung stage iv